FDA Scientists Take Recombinant Step Toward Faster Development Of Flu Vaccines
Executive Summary
Scientists at FDA have taken a step toward speeding the approval of influenza vaccines: They have demonstrated a faster way to produce the reagent used to evaluate a vaccine's potency.
You may also be interested in...
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.